Sponsored
Bharat Bio successfully completes Phase III trials of new oral cholera vaccine Hillchol
Posted
Bharat Biotech's oral cholera vaccine, Hillchol, has demonstrated successful Phase III clinical trial results, proving effective against both Ogawa and Inaba serotypes. The vaccine exhibited a significant rise in vibriocidal antibodies and maintained a strong safety profile across all age groups. With production capacity of 200 million doses, Hillchol can address the global cholera crisis and vaccine shortages.
Search
Categories
- National
- International
- Business
- Technology
- Health
- Education
- Sports
- Entertainment
- Travel
- Environment
- Science
- Law
- Agriculture
- Real Estate
- Opinion
- Religion
- Weather
- Automotive
- Social Issues
- Culture
- Sci-Fi & Future
Read More
Heated exchange erupts between PAC Chair Pokharel and lawmaker Modi
KATHMANDU: A verbal dispute erupted between Rishikesh Pokharel, Chairperson of the Public...
German industry crisis: Can cheap power help?
German industries face high electricity costs. This worries leaders. The new government under...
Suniel on why B-town stars were silent on Operation Sindoor
Suniel Shetty, currently starring in 'Kesari Veer,' voiced his concerns about actors avoiding...